NN1213 / Novo Nordisk - LARVOL DELTA

The Amylin Receptor Selective Agonist NN1213 Reduces Food Intake and Body Weight in Rats without Decreasing Calcium Plasma Levels (ADA 2025) - "Cagrilintide and eloralintide are both AMYR and CTR agonists whereas NN1213 is a selective AMYRs agonist that also decreases body weight in rats."

Preclinical • Metabolic Disorders • Obesity

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=353 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed

Metastases • Trial completion • Breast Cancer • Castration-Resistant Prostate Cancer • Colorectal Cancer • Genito-urinary Cancer • Hepatology • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor

NCI-2013-02103: Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma (clinicaltrials.gov) - P1/2 | N=75 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

IO biomarker • Trial completion date • Trial primary completion date • Cutaneous Melanoma • Melanoma • Oncology • Solid Tumor • BCL2 • PTEN

A Study on How NNC0174-1213 Works in People With Overweight or Obesity. (clinicaltrials.gov) - P1 | N=177 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - P1 | N=31 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Nov 2024 ➔ Mar 2025 | Trial primary completion date: Nov 2024 ➔ Mar 2025

Metastases • Trial completion date • Trial primary completion date • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor

VNC-152-101: Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer (clinicaltrials.gov) - P1 | N=110 | Completed | Sponsor: Vincerx Pharma, Inc. | Active, not recruiting ➔ Completed

Combination therapy • Metastases • Monotherapy • Trial completion • Oncology • MYC

Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29) (clinicaltrials.gov) - P2 | N=28 | Completed | Sponsor: Yonsei University | N=18 ➔ 28

Enrollment change • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (clinicaltrials.gov) - P1 | N=78 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Metastases • Trial completion date • Trial primary completion date • Colorectal Cancer • Cutaneous Melanoma • Genito-urinary Cancer • Melanoma • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Renal Cell Carcinoma • Sarcoma • Solid Tumor • CD4 • CD8 • CTAG1B • FGF • HGF • MLANA

Cabozantinib S-malate in Treating Patients with Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery (clinicaltrials.gov) - P2 | N=21 | Completed | Sponsor: M.D. Anderson Cancer Center | Active, not recruiting ➔ Completed

Metastases • Surgery • Trial completion • CNS Tumor • Endocrine Cancer • Oncology • Solid Tumor

A Study on How NNC0174-1213 Works in People With Overweight or Obesity. (clinicaltrials.gov) - P1 | N=177 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P1 trial • Genetic Disorders • Obesity

Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors (clinicaltrials.gov) - P=N/A | N=333580 | Completed | Sponsor: Boehringer Ingelheim | N=99000 ➔ 333580

Enrollment change • Acute Kidney Injury • Chronic Kidney Disease • Diabetes • Hepatology • Infectious Disease • Liver Failure • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Women Informed to Screen Depending on Measures of Risk (Wisdom Study) (clinicaltrials.gov) - P=N/A | N=100000 | Recruiting | Sponsor: University of California, San Francisco | Trial completion date: Dec 2025 ➔ Sep 2025 | Trial primary completion date: Dec 2025 ➔ Sep 2025

Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor

Physical Activity and Sedentary Behavior Change; Impact on Lifestyle (clinicaltrials.gov) - P=N/A | N=308 | Completed | Sponsor: University of Pittsburgh | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders

Dopamine and Motor Learning in Cerebral Palsy (clinicaltrials.gov) - P=N/A | N=28 | Completed | Sponsor: National Institutes of Health Clinical Center (CC) | Recruiting ➔ Completed | N=120 ➔ 28 | Trial completion date: May 2025 ➔ Nov 2024

Enrollment change • Trial completion • Trial completion date • Cerebral Palsy • CNS Disorders • BDNF • COMT • DRD2

Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation (clinicaltrials.gov) - P3 | N=112 | Completed | Sponsor: Suleyman Demirel University | Active, not recruiting ➔ Completed

Trial completion • Atrial Fibrillation • Cardiovascular

Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East Africa (clinicaltrials.gov) - P=N/A | N=7350 | Active, not recruiting | Sponsor: Oslo University Hospital | N=1350 ➔ 7350 | Trial completion date: Dec 2024 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Enrollment change • Trial completion date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery (clinicaltrials.gov) - P2 | N=40 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

IO biomarker • Surgery • Trial completion date • Trial primary completion date • Leiomyosarcoma • Liposarcoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Undifferentiated Pleomorphic Sarcoma • PD-L1